Technology ID
E-267-2012

Human Cell Line for Studies on Signaling and Endocrine Cancer

Linked ID
NCI-E-267-2012
Inventors
Constantine Stratakis (NICHD)
Lead Inventors
Constantine Stratakis (NICHD)
Development Status
Discovery (Lead Identification)
Applications
Research Materials
ICs
NICHD
Commercial Applications
  • Studies on multiple tumor formation associated with Carney Complex.
  • Characterization of cAMP-mediated mechanisms of endocrine tumor formation.
  • Studies of a large variety of cAMP-mediated processes in normal physiology and disease.
The first known immortalized cell line with a naturally-occurring inactivating mutation in PRKAR1A, the regulatory subunit type 1A (R1alpha) of protein kinase A (PKA), which is associated with tumor formation.PKA isozyme balance is critical for the control of cAMP signaling and related cell cycle and proliferation changes. Aberrant cAMP signaling has been linked to adrenocortical and other, mostly endocrine, tumors. Inactivating mutations in the PRKAR1A gene are a known cause of Carney Complex - an autosomal dominant multiple neoplasia syndrome associated with skin, heart, and other myxomas and a variety of endocrine tumors.
Competitive Advantages
  • First known immortalized cell line with a naturally-occurring inactivating mutation in the  PRKAR1A gene.

Request More Info

Licensing Contact